Our Mission

KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group, Inc. (OTC: KRTL), is a research and development company that has obtained a Ministry of Food and Drug Safety (MFDS), formerly known as the Korea Food & Drug Administration (KFDA) approval for psilocybin and CBD research. KRTL Biotech is looking to collaborate and partner with universities and biotech companies to facilitate this venture.

 

KRTL Biotech is instituting a facet of studies, with pharmaceutical-grade resources and technologies designed to help synthesize research and expedite the achievement of goals. Its scientists are leaders in cancer and neurology research, with over 100 years of experience in the biotechnology industry.

 

KRTL is poised to assist the medical and psychological community in the treatment of specific disorders, which include but not limited to pain resulting from cancer treatment, autism, PTSD, ADHD, depression, addiction, improvement in concentration and varies psychological illnesses.